Skip to contentB
Boston Scientific Corp
B
BSXBoston Scientific Corp Q3 2022 · 10-Q
Revenue$3.17B$3.17B+8.1% vs Q3 2021 Net Income$188.00M$188.00M−55.1% vs Q3 2021 EPS Diluted$0.12$0.12−57.1% vs Q3 2021 Gross Profit$2,191,000,000+7.8% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Boston Scientific Corp · CIK 885725 · Engraved from SEC EDGAR
Operating Cash Flowderived$470,000,000+1.1% Free Cash Flowderived$320,000,000−10.6% Margins · derivedGross margin69.1%−0.2 pt vs Q3 2021
Operating margin11.3%−1.9 pt vs Q3 2021
Net margin5.9%−8.4 pt vs Q3 2021
ended Sep 30, 2022 · filed Nov 3, 2022 · 34 d after period end